Bio Medica Laboratories Limited (NSE:BMLL)
India · Delayed Price · Currency is INR 145.35
-6.60 (-4.34%)
At close: Nov 6, 2026
Bio Medica Laboratories Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 430.9 | 383.2 | 152.49 | 162.28 | 212.25 | |
Revenue Growth | 12.45% | 151.29% | -6.03% | -23.54% | 64.21% |
Cost of Revenue | 176.12 | 191.5 | 67.42 | 115.7 | 167.8 |
Gross Profit | 254.78 | 191.69 | 85.07 | 46.58 | 44.45 |
Selling, General & Admin | 30.51 | 19.45 | 17.03 | 18.12 | 17.27 |
Other Operating Expenses | 24.33 | 17.27 | 11.66 | 11.35 | 8.26 |
Operating Expenses | 66.47 | 46.78 | 39.8 | 34.44 | 28.8 |
Operating Income | 188.31 | 144.92 | 45.28 | 12.14 | 15.65 |
Interest Expense | -23.94 | -13.28 | -9.38 | -7.3 | -7.68 |
Interest & Investment Income | 0.07 | 0.02 | 0.08 | 0.21 | - |
Currency Exchange Gain (Loss) | 0.03 | 0.03 | - | -0 | - |
Other Non Operating Income (Expenses) | -1.84 | -0.27 | -0.28 | -0.45 | -0 |
EBT Excluding Unusual Items | 162.63 | 131.43 | 35.7 | 4.6 | 7.97 |
Gain (Loss) on Sale of Assets | -0.18 | - | - | - | - |
Other Unusual Items | 0.09 | - | - | - | - |
Pretax Income | 162.54 | 131.43 | 35.7 | 4.88 | 7.97 |
Income Tax Expense | 43.67 | 34.39 | 9.38 | 1.28 | 2.08 |
Earnings From Continuing Operations | 118.87 | 97.04 | 26.31 | 3.6 | 5.89 |
Minority Interest in Earnings | -1.07 | - | - | - | - |
Net Income | 117.81 | 97.04 | 26.31 | 3.6 | 5.89 |
Net Income to Common | 117.81 | 97.04 | 26.31 | 3.6 | 5.89 |
Net Income Growth | 21.40% | 268.78% | 631.22% | -38.90% | 34.10% |
Shares Outstanding (Basic) | 9 | 9 | 9 | 9 | 9 |
Shares Outstanding (Diluted) | 9 | 9 | 9 | 9 | 9 |
Shares Change | - | -0.00% | - | -0.00% | 0.00% |
EPS (Basic) | 12.83 | 10.57 | 2.87 | 0.39 | 0.64 |
EPS (Diluted) | 12.83 | 10.57 | 2.87 | 0.39 | 0.64 |
EPS Growth | 21.41% | 268.75% | 631.22% | -38.90% | 34.11% |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | -90.44 | -45.74 | -23.13 | -10.58 | - |
Free Cash Flow Per Share | -9.85 | -4.98 | -2.52 | -1.15 | - |
Gross Margin | 59.13% | 50.02% | 55.79% | 28.70% | 20.94% |
Operating Margin | 43.70% | 37.82% | 29.69% | 7.48% | 7.37% |
Profit Margin | 27.34% | 25.32% | 17.26% | 2.22% | 2.77% |
Free Cash Flow Margin | -20.99% | -11.94% | -15.17% | -6.52% | - |
EBITDA | 199.95 | 154.97 | 56.38 | 17.1 | 18.93 |
EBITDA Margin | 46.40% | 40.44% | 36.97% | 10.54% | 8.92% |
D&A For EBITDA | 11.63 | 10.05 | 11.1 | 4.97 | 3.28 |
EBIT | 188.31 | 144.92 | 45.28 | 12.14 | 15.65 |
EBIT Margin | 43.70% | 37.82% | 29.69% | 7.48% | 7.37% |
Effective Tax Rate | 26.86% | 26.16% | 26.28% | 26.21% | 26.13% |
Revenue as Reported | 431.13 | 383.25 | 153.44 | 162.77 | 214.37 |